Signaling a vote of confidence in the company, a $1.1M subscription has been secured from existing and new investors that will help boost R&D activities. The financing is a prelude to a $2.5M post-seed round planned to close by late Q1/2022.
Copyright 2022 © Ophthalmic Sciences Ltd. | IOPerfect™ is a trademark of Ophthalmic Sciences Ltd.
Privacy policy | Terms of use | All rights reserved
Our pilot study is underway!
Ophthalmic Sciences is working with Assuta Medical Center in Ashdod and Assuta Hashalom on the study of its novel glaucoma monitoring technology, see our news section for study details.
Contact us for more information.
